DiamondRock Hospitality reported a 65.7% increase in net income to $33.3 million in Q3 2026, driven by higher hotel revenues and operating efficiencies. The company acquired The Bellmoor Inn & Spa for $31 million, expanding its portfolio to 35 hotels. It raised its full-year 2026 guidance, expecting stronger revenue per available room and adjusted EBITDA growth. Looking ahead, DiamondRock anticipates continued earnings growth and capital deployment flexibility in 2027.
DiamondRock Hospitality's Q3 2026 results provide context for real estate market activity. For readers following the sector, here is Pluang's market snapshot as of Nov 04, 2026 03:02 WIB: Out of 47 priced US real estate stocks, 16 advanced and 30 declined. Equinix Inc (EQIX) rose 1.50% to USD 1,008.57 with 100% buy orders, while Park Hotels & Resorts Inc. (PK) fell 1.34% to USD 16.61, and Orion Office REIT Inc (ONL) gained 1.23% to USD 2.47 with 100% sell orders.
Nova Klúbburinn hf. has completed a share buyback program, acquiring 122,699,386 shares at an average price of ISK 3.26 per share. The buyback was part of an inverse offer process with valid bids for 159,526,476 shares. The company accepted bids up t...
AMC Entertainment will release its Q3 2026 earnings on Nov. 4, following a year-over-year increase in North American box-office receipts to about $3.1 billion from $2.5 billion in Q3 2025. The quarter featured major film releases like Spider-Man: Bra...
Pomerantz LLP is investigating Erasca, Inc. following the termination of its COO, Nicholas Chetwyn, which led to a nearly 10% drop in the company's stock price. The investigation focuses on whether Erasca and its executives engaged in securities frau...
Pomerantz LLP is investigating claims against Yiren Digital Ltd. for possible securities fraud following the company's disclosure of a 34% revenue decline and a significant net loss in Q4 2025. The company also reported increased delinquency rates an...
Pomerantz LLP is investigating Syndax Pharmaceuticals following the company's announcement that its Phase 2 trial for axatilimab in idiopathic pulmonary fibrosis failed to meet its primary endpoint. This news caused Syndax's stock to drop by 2.59% on...
